Back to Home
Free CE/CMEVideo

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

Release Date

December 5, 2025

Expiration Date

December 6, 2026

Credits

13.75 CME, NCPD

Release Date: December 5, 2025

Expiration Date: December 5, 2026

Activity Overview

This educational activity is an archive of the live presentation held on November 12-14, 2025.

For more information about this educational activity, the faculty, and disclosures, please click here.

Target Audience

This educational activity is intended for oncologists, hematologists, nurses, advanced practice providers, pharmacists, radiotherapists, immunologists, fellows, researchers, pathologists, and other health care professionals involved in or interested in the treatment and management of patients with cancer, including solid tumors and hematologic malignancies.

Learning Objectives

Upon successful completion of this activity, learners will be better able to:

  • Describe the supporting evidence for novel biomarker-testing approaches that guide the use of targeted therapies and/or modification of treatment plans
  • Evaluate efficacy and safety data from recent pivotal trials investigating new and emerging therapies
  • Develop personalized treatment plans based on evolving evidence, guideline recommendations, and individual patient/disease characteristics
  • Apply strategies to identify and mitigate treatment-related adverse effects associated with novel therapies and combination regimens
43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

GET STARTED WITH THIS PROGRAM:

Register now to gain access to this program.

Create AccountAlready Registered? Login Here

Accreditation/Credit Designation

Physicians’ Education Resource®, LLC, is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians.

Physicians’ Education Resource®, LLC, designates this enduring material for a maximum of 13.75 AMA PRA Category 1 Credits™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.

Physicians’ Education Resource®, LLC, is approved by the California Board of Registered Nursing, Provider #16669, for 13.75 Contact Hours.

Acknowledgment of Commercial Support

This activity is supported by educational grants from AstraZeneca Pharmaceuticals; Boehringer Ingelheim Pharmaceuticals, Inc; Daiichi Sankyo, Inc; Eisai Inc; Exact Sciences, Inc.; Exelixis, Inc; Incyte Corporation; Merck Sharp & Dohme LLC; Partner Therapeutics, Inc; Pfizer, Inc; Stemline Therapeutics, Inc; and Taiho Oncology.

Course

43rd Annual CFS®: Innovative Cancer Therapy for Tomorrow™

Create Account